- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07098377
- Original Trial
Microbiota in Children With Severe Burn Injury (MIBUS)
Gut, Nasopharyngeal, and Skin Microbiota in Children With Severe Burn Injury: the Role in Infectious Complications in Burn Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pediatric burns (0-14 years) make up 26% of emergency room admissions for burns, with 73% of cases in children under 5 years old. The most common burns are thermal from boiling liquids, followed by open flames and fireworks. Severe burns (>20% of body surface area) provoke a systemic inflammatory response that causes hypovolemia, tissue hypoperfusion, and metabolic stress, establishing a vicious cycle that is difficult to break.
Burn trauma can also compromise the intestinal barrier, composed of cellular junctions (tight junctions), damage to which increases intestinal permeability. This promotes the passage of luminal contents into the systemic circulation, aggravating the immune and inflammatory response. Gut dysfunction is often accompanied by dysbiosis of the microbiota, with risk of bacterial translocation to sterile organs (liver, lungs, brain), contributing to systemic complications in critically ill patients.
The study hypothesizes that burn trauma increases intestinal permeability, promoting bacterial translocation and anticipating infectious complications. Analyzing microbial populations at exposed sites (skin, gut, BAL) during trauma and pediatric ICU care may help to better understand the origin of septic complications.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Roma, Italy, 06132
- Fondazione Policlinico Universitario A. Gemelli IRCCS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- signs and/or symptoms of burn injury
Exclusion Criteria:
- major congenital malformation
- Antibiotic treatment 48 hours prior to admission
- failure to provide informed consent to participate in the protocol
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
burns affected
|
nasopharyngeal swab for biological sample analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
intestinal microbiota variation in burnt children
Time Frame: 21 days
|
concentration of microbiota population in pediatric population severely burnt
|
21 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Orazio Genovese, Fondazione Policlinico Universitario A. Gemelli, IRCCS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7327
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn
-
Dr Muhammad Naveed ShahzadNot yet recruitingSilver Sulfadiazine With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Partial-Thickness BurnsPartial-Thickness Burn, Thermal BurnPakistan
-
Indonesia UniversityRecruitingBurn Degree Second | Burn Degree ThirdIndonesia
-
Xequel Bio, Inc.United States Department of DefenseWithdrawnThermal Burn | Second Degree Burn
-
Integra LifeSciences CorporationWithdrawnBurn Scar | Burn Injury | Skin Grafting | Burn Wounds - Partial Thickness (2nd Degree)
-
The First Affiliated Hospital of Xinxiang Medical...Not yet recruitingBurn | Burn Degree Second | Burn Contracture of Skin
-
XenoTherapeutics, Inc.Joseph M. Still Research Foundation, Inc.RecruitingWound Heal | Thermal Burn | Burn Degree Second | Burns Degree Third | Burn (Disorder)United States
-
General Electric ResearchTerminatedBurn Wound | 2nd Degree Burn of the SkinUnited States
-
University Hospital, LinkoepingCompletedBurn Scar | Burns | Burn Second DegreeSweden
-
University Hospital Schleswig-HolsteinUniversity of LuebeckRecruitingSecond-degree Burn | Third-Degree BurnGermany
-
Jason SperryUnited States Department of DefenseNot yet recruitingBurn Injury | Thermal BurnUnited States
Clinical Trials on nasopharyngeal swab for biological sample analysis
-
Zhongnan HospitalInstitute of Biotechnology, Academy of Military Medical Sciences, PLA of...RecruitingCOVID-19 | InfluenzaChina
-
University of CologneCity Council of Cologne, Department of Public Health, NRW, Germany; City Council...CompletedSARS-CoV-2 Infection | COVID-19 Respiratory InfectionGermany
-
Association Clinique Thérapeutique Infantile du...PfizerRecruitingChildren, Only | Antibiotic Resistant Strain | Nasopharyngeal CarriageFrance
-
Rigshospitalet, DenmarkCompleted
-
Hadassah Medical OrganizationLondon North West Healthcare NHS TrustRecruitingCOVID-19 | Inflammatory ResponseIsrael
-
Assistance Publique - Hôpitaux de ParisRecruitingSARS-CoV2 InfectionFrance
-
GlaxoSmithKlineCompletedRespiratory DisordersUnited Kingdom
-
Radboud University Medical CenterUnknown
-
University Health Network, TorontoCompletedCovid19 | Healthcare WorkerCanada